Mark Humayun, MD, PhD
University of Southern California, Los Angeles, Calif.
Dr. Humayun is developing a metabolic prosthesis to treat blindness caused by diabetic retinopathy.
Dr. Mark Humayun is the Cornelius J. Pings Chair in Biomedical Sciences; Professor of Ophthalmology, Biomedical Engineering, and Cell and Neurobiology; Director, Institute for Biomedical Therapeutics and Director, USC Eye Institute, University of Southern California, Los Angeles.
Dr. Humayun joined Doheny Eye Institute and the Keck School of Medicine at the University of Southern California (USC) in 2001. He has continued his research in nanotechnology to develop a retinal implant that he began in his previous position as Director of the Intraocular Retinal Prosthesis Lab, Wilmer Ophthalmological Institute at Johns Hopkins.
At USC, Dr. Humayun led the team that developed the Argus II implant, which has the capability to partially restore sight to some people blinded by retinitis pigmentosa. In Feb. 2013, the U.S. Food and Drug Administration approved the Argus II for use in the United States.
Dr. Humayun continues to pursue new treatments for the most debilitating and challenging eye diseases through advanced engineering. Leading a team of more than 30 faculty and 200 students from 15 different institutes, Dr. Humayun is exploring additional therapies for retinal degenerations such as retinitis pigmentosa and diabetic retinopathy, age-related macular degeneration and retinovascular diseases such as vein occlusions and glaucoma.
Dr. Humayun completed his medical degree at Duke University Medical School and served his residency at Duke Eye Center, Durham, NC. He earned his doctorate in Biomedical Engineering at the University of North Carolina at Chapel Hill and completed his fellowship training in vitreoretinal disease at the Wilmer Ophthalmological Institute at Johns Hopkins, Baltimore, Md.